{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:08:11Z","timestamp":1780603691799,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Basilea Pharmaceutica International Ltd."},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600002C"],"award-info":[{"award-number":["HHSO100201600002C"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.diagmicrobio.2019.01.015","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T09:07:25Z","timestamp":1548580045000},"page":"304-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016\u20132017)"],"prefix":"10.1016","volume":"94","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal A.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0005","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cid\/cis1006","article-title":"Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection","volume":"56","author":"Ammerlaan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0010","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1128\/JCM.42.7.3356-3358.2004","article-title":"Quality control guidelines for BAL9141 (RO 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used","volume":"42","author":"Anderegg","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2004.05.003","article-title":"Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002)","volume":"50","author":"Biedenbach","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1744-8603-9-58","article-title":"Incentives for new antibiotics: the options market for antibiotics (OMA) model","volume":"9","author":"Brogan","year":"2013","journal-title":"Glob Health"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0030","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: Eleventh edition","article-title":"M07Ed11E","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0035","series-title":"Performance standards for antimicrobial susceptibility testing: 28th informational supplement","article-title":"M100Ed28E","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0040","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.00029-07","article-title":"Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae","volume":"51","author":"Davies","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0045","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/clinids\/23.6.1234","article-title":"Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality","volume":"23","author":"Edmond","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0050","author":"EUCAST"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0055","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.02465-14","article-title":"Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0060","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.cmi.2015.12.002","article-title":"The negative impact of antibiotic resistance","volume":"22","author":"Friedman","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005\u20132006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1469-0691.12195","article-title":"Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe","volume":"19","author":"Goto","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0075","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/CMR.00002-14","article-title":"Population-based epidemiology and microbiology of community-onset bloodstream infections","volume":"27","author":"Laupland","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0080","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/1469-0691.12160","article-title":"Long-term consequences of severe infections","volume":"19","author":"Leibovici","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0085","first-page":"4565","article-title":"Ceftobiprole for the treatment of pneumonia: a European perspective","volume":"9","author":"Liapikou","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-110-1-9","article-title":"Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay","volume":"110","author":"Martin","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jinf.2014.01.014","article-title":"Decreasing incidence rates of bacteremia: a 9-year population-based study","volume":"69","author":"Nielsen","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QCO.0000000000000182","article-title":"The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria","volume":"28","author":"Perez","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0110","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1086\/320187","article-title":"Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program","volume":"32","author":"Pfaller","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2017.12.020","article-title":"Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary gram-positive and -negative organisms collected from Europe (2015)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijantimicag.2016.06.014","article-title":"A one health approach to antimicrobial resistance surveillance: is there a business case for it?","volume":"48","author":"Queenan","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0130","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s40265-014-0273-x","article-title":"Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia","volume":"74","author":"Syed","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cid\/ciw649","article-title":"The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis","volume":"64","author":"Timbrook","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0140","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archinte.167.8.834","article-title":"Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota","volume":"167","author":"Uslan","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhin.2009.12.006","article-title":"Hospital-acquired, laboratory-confirmed bloodstream infections: linking national surveillance data to clinical and financial hospital data to estimate increased length of stay and healthcare costs","volume":"75","author":"Vrijens","year":"2010","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0150","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.diagmicrobio.2010.10.032","article-title":"In vitro activity of ceftobiprole against frequently encountered aerobic and facultative gram-positive and gram-negative bacterial pathogens: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Walkty","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0155","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0160","series-title":"Summary of product characteristics","author":"Zevtera","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2019.01.015_bb0165","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318306254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318306254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:51:55Z","timestamp":1760003515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318306254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0732889318306254"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.01.015","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016\u20132017)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}